



WHAT CYCLE 2011 MADE POSSIBLE

CYCLE FOR SURVIVAL FUNDS RESEARCH THAT SAVES LIVES

Every dollar raised by Cycle for Survival goes directly to Memorial Sloan-Kettering Cancer Center for lifesaving research on rare cancers. Since 2007, Cycle for Survival has raised over **\$9 million and has directly funded 25 clinical trials and research studies**, providing new treatment options and renewed hope to the millions touched by rare cancers around the world.

MEMORIAL SLOAN-KETTERING CANCER CENTER

Cycle for Survival is proud to be a critical component of Memorial Sloan-Kettering Cancer Center (MSKCC). Founded in 1884, MSKCC is the world's oldest and largest institution dedicated exclusively to the care, control, and cure of cancer. Its legacy of innovation is unparalleled: MSKCC has produced more FDA-approved drugs for the treatment of cancer than any other single academic institution. The Center also treats over 400 types of cancer each year and is proud to count many of the world's most renowned and accomplished leaders in rare cancer research and care among its clinical staff.

THE FUNDS RAISED ARE TURNKEY

Cycle for Survival funds are quickly allocated to the most promising clinical trials and research studies at MSKCC within six months of each event, dramatically reducing the time it takes to fuel the research discoveries that lead to better treatments for cancer patients. In some cases, Cycle's direct funding has reduced the time it takes for treatments and therapies to go from benchtop to bedside from 5 years down to 18 months.

THE PROGRESS IS REAL

Since research on rare cancers is often drastically underfunded, there is a great need and extraordinary opportunity for significant advancements. What's more, new insights into rare cancers may well hold the keys to breakthroughs elsewhere.

2011 PROJECTS FUNDED BY CYCLE FOR SURVIVAL INCLUDE:

- Cancer Biology and Genetics Program scientists are working to determine whether inhibiting a gene called CSF-1R might suppress the development of certain brain tumors called gliomas.
- Radiologists are working to develop innovative ways to measure the effects of new therapies on a particular form of pancreatic tumor called pancreatic neuroendocrine tumors.
- Physicians in the Head and Neck Medical Oncology Service are conducting a phase II study of a drug called MK-2206 in patients with progressive recurrent/metastatic adenoid cystic carcinoma, a rare cancer that often occurs in the head and neck.
- Investigators in the Cancer Biology and Genetics Program are studying residual and recurrent glioma to learn more about how brain tumors cells manage to resist conventional therapies.
- Scientists in the Molecular Biology Program are exploring the role of a promising new drug called PDO331991 in the treatment of glioma.
- Physicians in the Lymphoma Service are studying innovative new therapies for T-cell lymphomas.
- Physicians in the Department of Pathology are using whole genome sequencing -- a process that determines the complete DNA sequence of an organism's genome at a single time -- to study a rare but aggressive cancer called urothelial neoplasm.
- Physicians in the Gynecologic Medical Oncology Service are employing comprehensive molecular profiling of low-grade serous and serous borderline ovarian cancer.
- A study conducted within the sarcoma consortium (a collaboration of 20 clinical centers) has shown that a novel combination of two drugs controls tumor growth better than either drug administered alone. And based on preclinical data made possible by Cycle funds, MSKCC has been approved to begin the first clinical trial to test a drug that inhibits a protein called Aurora Kinase A. The study will have the support of the NCI and will be brought directly into the sarcoma consortium.

www.cycleforsurvival.org

888-72-CYCLE or 646-227-2762 • cycleforsurvival@mskcc.org • [@cycle4survival](https://twitter.com/cycle4survival)

Memorial Sloan-Kettering Cancer Center • 633 Third Avenue, 28th Floor • New York, NY 10017